How does testosterone therapy affect blood pressure and what monitoring and management steps are recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Testosterone Effect on Blood Pressure

Testosterone replacement therapy (TRT) has a neutral to potentially beneficial effect on blood pressure in men with confirmed hypogonadism, though monitoring remains essential due to formulation-specific risks and individual patient factors.

Primary Evidence on Blood Pressure Effects

The most authoritative guideline evidence indicates that TRT demonstrates a neutral or possible beneficial effect on blood pressure 1. This is supported by the 2020 American College of Physicians evidence report, which found that oral testosterone formulations specifically showed increased blood pressure (leading to FDA contraindication for age-related hypogonadism), but this does not apply to intramuscular or transdermal preparations 2.

Recent High-Quality Evidence

The most recent and robust data comes from a 2024 prospective registry study showing that testosterone undecanoate (TU) was associated with significant reductions in systolic, diastolic, and pulse pressure 3. In men never on antihypertensive agents, median reductions were:

  • Systolic BP: -12.5 mmHg
  • Diastolic BP: -8.0 mmHg
  • Pulse pressure: -6.0 mmHg

Critically, only 1 of 152 men not on antihypertensives at baseline required new antihypertensive therapy during follow-up, while 33 of 202 men on antihypertensives had their medications discontinued 3.

Critical Nuances and Contradictory Evidence

However, a 2024 randomized controlled trial in opioid-treated men with hypogonadism showed the opposite effect: TRT increased office systolic BP by 6.2 mmHg compared to a 7.0 mmHg decrease with placebo (mean difference 13.2 mmHg, p=0.01) 4. This increase was directly correlated with rising hematocrit levels—for every 10 mmHg increase in systolic BP, hematocrit increased by 0.3% 4.

Key Distinction: Patient Population Matters

The divergent findings highlight that BP response depends heavily on baseline characteristics:

  • Men with higher baseline BP experience greater reductions with TRT 3
  • Men with obesity or upper-normal hematocrit are more susceptible to BP increases 4
  • Opioid-treated men may represent a uniquely vulnerable population 4

FDA Drug Label Warnings

The FDA label for testosterone cypionate does not specifically list hypertension as a precaution, though it mandates monitoring of hematocrit levels due to polycythemia risk (3-44% depending on formulation) 5. The FDA has specifically contraindicated oral testosterone undecanoate due to demonstrated BP increases 2.

Monitoring and Management Algorithm

Pre-Treatment Assessment

  • Measure baseline BP (office and ideally 24-hour ambulatory)
  • Check baseline hematocrit and hemoglobin
  • Assess BMI and metabolic status
  • Identify if hypogonadism is organic vs. functional (obesity-related)

During Treatment Monitoring

Hematocrit monitoring is mandatory as it directly mediates BP effects:

  • Check at 3 months, then every 6-12 months 1, 5
  • Current guidelines suggest action at hematocrit >0.54, though this threshold lacks strong scientific basis 6
  • The BP increase correlates with hematocrit rise, particularly in susceptible patients 4

Blood pressure monitoring:

  • Check BP at each visit, especially in first 6 months
  • Higher vigilance needed in men with:
    • Obesity (BMI >30)
    • Baseline hematocrit in upper normal range
    • Pre-existing cardiovascular risk factors
    • Concurrent opioid therapy

Formulation Considerations

  • Intramuscular preparations carry higher erythrocytosis risk (up to 44%) compared to transdermal (3-18%) 1
  • Oral testosterone undecanoate is contraindicated for age-related hypogonadism due to BP increases 2
  • Testosterone gel shows smaller increases in hemoglobin/hematocrit 7

Common Pitfalls to Avoid

  1. Treating functional hypogonadism first-line with TRT: In obesity-related hypogonadism, lifestyle intervention and GLP-1/GIP agonists normalize testosterone in 81-89% of cases, avoiding TRT risks entirely 8

  2. Ignoring the hematocrit-BP connection: Rising hematocrit is the primary mechanism for BP increases during TRT 4. Monitor both together, not in isolation.

  3. Assuming all formulations are equivalent: Oral preparations increase BP; transdermal may be safer for men at cardiovascular risk 2, 7

  4. Overlooking baseline risk factors: Men with obesity, upper-normal hematocrit, or opioid use require more intensive monitoring 4

Cardiovascular Safety Context

The 2023 TRAVERSE trial demonstrated non-inferiority of TRT versus placebo for major adverse cardiovascular events (MACE) in older men with confirmed hypogonadism (HR 0.96,95% CI 0.78-1.17) 8. Earlier meta-analyses found no increased cardiovascular events with TRT, though studies were limited by short duration and small sample sizes 9.

The evidence supports that when TRT is titrated to physiological levels in men with confirmed organic hypogonadism, it does not increase MACE risk, though non-MACE signals (atrial fibrillation, venous thromboembolism) warrant ongoing vigilance 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.